← SynDRA
RIZATRIPTAN
SynDRA canonical compound SYN0002492 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | HTR1F |
|---|
| Mechanism of action | Serotonin receptor agonist |
|---|
| Indication | migraine headache |
|---|
| Disease area | neurology/psychiatry |
|---|
All known targets
- HTR1D
- HTR1B
- HTR1F
- HTR1A
- HTR1E
- CYP2D6
- HTR2A
- HTR2C
- Htr2a
- Htr3a
- Htr3b
Mechanisms of action (all sources)
- Serotonin receptor agonist
- HTR1B AGONIST
- Serotonin 1b (5-HT1b) receptor agonist
- HTR1D AGONIST
- Serotonin 1d (5-HT1d) receptor agonist
- HTR1A FULL AGONIST
- HTR1B PARTIAL AGONIST
- HTR1D FULL AGONIST
- HTR1E FULL AGONIST
- HTR1F FULL AGONIST
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- HRH1
- ADORA1
- MC3R
- NTSR1
- NR3C1
- NPY2R
- NPY1R
- MLNR
- MC4R
- MAOA
- GPR17
- KCNH2
- HTR7
- HTR6
- HTR2B
- HRH3
- HRH2
- OPRD1
- OPRK1
- OPRM1
- SLC29A1
- TACR1
- SLC6A4
- SLC6A3
- SLC6A2
- SLC47A2
- SLC47A1
- SLC22A3
- PDE3A
- SCN5A
- PTGS2
- POU2F2
- POU2F1
- PGR
- PDE4D
- HDAC6
- GIPR
- ADORA2A
- GHSR
- CCKBR
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- 5HT1A
- 5HT1E
- 5HT1F
- KCMA1
- SNCA
- SYUA
- TP53
Drug classes
- Neurotransmitter Agents
- Serotonin Agents
- Serotonin Receptor Agonists
- Serotonin 1b Receptor Agonists
- Serotonin 1d Receptor Agonists
- Serotonin-1b and Serotonin-1d Receptor Agonist
ATC classes
- N02C · ANTIMIGRAINE PREPARATIONS
Cross-references
Synonyms
- MAXALT
- MAXALT-MLT
- Maxalt
- RIZAFILM
- RIZATRIPTAN BENZOATE
- Rizafilm
- SYMBRAVO
- MK-0462
- risatriptan
- rizatriptan benzoate
- L-705126
- MK-462 FREE BASE
- Risatriptan
- Rizatriptanum
- Rizatriptan benzoat
- MK 462 free base
- Maxalt (TN)
- Rizaliv (TN)
- Rizalt (TN)
- Rizatriptan (INN)
- Rizatriptan [INN:BAN]
- L 705126
- rizatriptanum
- DTXCID103565
- CHEBI:48273
- RefChem:58235
- N02CC04
- MK 462
- NCGC00095899-01
- RIZATRIPTAN [INN]
- UNII-51086HBW8G
- MFCD03840591
- RIZATRIPTAN [MI]
- GTPL51
- RIZATRIPTAN [VANDF]
- SCHEMBL26662
- RIZATRIPTAN [WHO-DD]
- MLS006010229
Reported adverse events
- Asthenia
- Headache
- Nausea
- Somnolence
- Arrhythmia
- Dizziness
- Pain
- Serotonin syndrome
- Seizure
- Vasospasm
- Gastrointestinal disorder
- Dysgeusia
Look up RIZATRIPTAN in the interactive SynDRA portal →